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Low Intracellular Proline: A Cause of Toxicity in Human RPE Cells? 
 
Sina Vahedi* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Introduction 
 
Gyrate atrophy of the choroid and retina (GA) is an 
autosomal recessive disease caused by mutations in 
the nuclear gene coding for the mitochondrial enzyme 
ornithine aminotransferase (OAT; Valle & Simell, 2001). 
The primary symptoms for this congenital metabolic 
disease include night blindness, myopia, cataracts, and 
progressive reduction in peripheral vision culminating in 
blindness by the age of forty. The loss of OAT leads to 
high plasma levels of the amino acid ornithine and low 
levels of proline and creatine (Valle & Simell, 2001).  
Our knowledge about the pathophysiology of 
GA is very limited: we do not know the mechanism for 
toxicity or the primary toxic species. However, we do 
know the following: first, the initial cells affected are the 
retinal pigmented epithelial (RPE) cells (Wang et al., 
1996); second, ornithine enters the cells primarily 
through the cationic amino acid transporter (CAT)-1 
(Kaneko et al., 2007); third, lowering plasma levels of 
ornithine prevents the progression of the disease 
(Wang et al., 2000). 
Since proper CAT-1 functioning is essential 
for the survival of the organism, this channel cannot be 
systemically blocked as a treatment for GA (Kaneko et 
al., 2007). The most efficient treatment has been 
reducing the plasma ornithine level by restricting the 
intake of its precursor arginine (Wang et al., 2000). This 
treatment is not without its problems. Only about 20% 
of the patients are able to follow this diet (Wang et al., 
2000), as it is highly restrictive and requires the patient 
to take many dietary supplements supplying the 
essential amino acids, vitamins, and minerals (Valle & 
Simell, 2001). 
Ueda et al. (1998) showed that treatment with 
proline prevented toxicity caused by high 
concentrations of ornithine in RPE cells lacking OAT. 
The authors suggest that low proline levels might be the 
primary cause of toxicity in GA. The study, however, 
provides inconclusive evidence to support the 
hypothesis. The levels of proline in the cell are not 
measured in the study, and toxicity to RPE cells by low 
levels of proline alone is not measured. The prospect 
that low proline levels cause GA cytotoxicity is an 
exciting one since dietary supplementation of proline is 
much easier than restriction of arginine. The cheaper 
and easier treatment that could result from this 
possibility necessitates an investigation into the role of 
proline in GA. 
 
Specific Aims 
 
Based on the research by Ueda and colleagues (1998), 
I will investigate the toxic effect of low proline levels in 
human RPE cells. I will render the cells incapable of 
biosynthesizing proline, which will enable me to control 
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the level of proline in the cell by varying its 
concentration in the serum.  
Secondly, I will vary the intracellular proline 
levels and correlate any toxicity observed with the 
amount of proline inside the cell. If low levels of 
intracellular proline cause toxicity, cell death should be 
independent of OAT activity but inversely proportional 
to the level of proline in the cell. It is therefore 
unnecessary to mimic the Ueda et al study and inhibit 
OAT in the cells (1998). 
 
Experimental Proposal 
 
The study conducted by Ueda et al. (1998) suggests 
that proline starvation might be the cause of toxicity in 
GA. However, the evidence for this is indirect and 
based on the cytoprotective role of proline in the 
experiment. To support the hypothesis that low proline 
levels cause RPE cell atrophy in GA, I will carry out 
experiments to show the correlation of low proline 
levels to cell death. 
 
Silencing the P5C Reductase Gene 
P5C reductase is the final enzyme required for the 
biosynthesis of proline (Ueda et al., 1998). To fully 
control the amount of proline in the cell, I shall silence 
the P5C reductase gene in the telomerase-immortalized 
hTERT-RPE cells purchased from Clontech. This will 
be done by stable retroviral transfection of a short 
interfering dsRNA coding region complementary to a 
region of the P5C reductase mRNA using the 
Knockout™ RNAi-Ready pSIREN-RetroQ vector from 
Clontech. The resulting RPE cells (P5Cr) will be 
incapable of biosynthesizing proline and will thus be 
maintained in proline rich media. Scrambled siRNA with 
no homology to any known human gene will be used as 
a control and shall be transfected the same way to give 
rise to scP5Cr cells. Northern blotting, using 
32
P labeled 
P5C reductase and GAPDH will be used to determine 
the effect of RNA interference on P5C reductase 
expression. If the RNAi treatment is successful we 
should not detect any P5C reductase RNA in the P5Cr 
cells, but should see it in the scP5Cr cells. The amount 
of GAPDH RNA produced will act to control the amount 
of cells. 
 
Toxicity Assay 
Toxicity will be evaluated using the [
3
H]Thymidine 
incorporation assay described by Ueda et al. (1998). 
The tritium labeling will enable us to detect the amount 
of DNA in the culture, which corresponds to the amount 
of cells present. The data will be normalized by 
comparing it to the amount of tritium in scP5Cr cell 
culture. Morphological changes in the cell will be 
evaluated by microscopy. 
 
Intracellular Proline Concentration 
The amount of proline in the cell shall be detected by 
high performance liquid chromatography after washing 
and lysing the cells. To account for the difference in the 
number of cells in each culture, the proline level will be 
reported as a ratio of the amount of proline to the 
amount of tritium in the cell culture detected by the 
[
3
H]Thymidine incorporation assay. 
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Effect of Different Proline Levels 
Since the P5Cr cells get all their proline from the 
media, their intracellular proline level can be varied by 
treating them with different concentrations of proline, 
starting from well below the physiological concentration 
of 150µM (Ueda et al., 1998) and working up to it. The 
scP5Cr cells shall be used as the control since they 
should contain physiological levels of proline. 
Intracellular proline concentration and toxicity will be 
measured using the assays described above. 
I believe that intracellular proline levels below 
the physiological level will be toxic to the P5Cr cells, 
leading to cell atrophy by a pathway other than 
apoptosis as reported by Ueda et al. (1998). If we 
observe no toxicity, it indicates that the cytoprotection 
due to proline observed by Ueda and colleagues was 
due to an unknown reason, which would need to be 
studied, and low proline levels were not the cause of 
toxicity. This is a probable outcome of this experiment, 
since the amount of proline needed to prevent toxicity 
(10mM) was much greater than the normal 
physiological concentration of proline (Ueda et al. 
1998).  
This experiment cannot tell us if toxicity due 
to proline starvation is caused by the same unknown 
pathway as in GA, but will provide useful evidence for 
the viability of proline supplementation as a treatment 
for GA. 
 
Conclusion 
 
This experiment will help determine if low proline levels 
lead to RPE cell death in GA. This knowledge will 
further our understanding of the pathophysiology in GA 
and prompt more research exploring it as a proline 
deficiency disorder. This study will also lead to informed 
trials attempting to prevent GA progression by proline 
supplementation, which is an easier and cheaper 
treatment than arginine restriction. 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication 
and should be cited as such only with the consent of 
the author. 
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